SURGICAL ONCOLOGY AND TUMOR MARKERS

Slides:



Advertisements
Similar presentations
Dr. Amal S. Ahmed Ass Prof.Clinical Pathology Suez Canal University
Advertisements

TUMOR MARKERS Prof. Dr.Yıldız DİNÇER.
Oncology The study of cancer. What is cancer? Any malignant growth or tumor caused by abnormal and uncontrolled cell division May be a tumor but it doesn’t.
Tumor Markers Lecture one By Dr. Reem Sallam. Objectives  To briefly introduce cancers, their incidence, some common terms, and staging system.  To.
Cancer.
Doç.Dr. Jale Çoban Klinik Biyokimya Uzmanı
Tumor Markers Lecture one By Dr. Waheed Al-Harizi.
What is Genetic Testing? And what is its value? Sherri J. Bale, Ph.D., FACMG President and Clinical Director GeneDx.
Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery
Lecture 4. Special chemistry Definition Special Chemistry is a subsection of the Chemistry Laboratory of the Division of Clinical Pathology. This includes.
Biomarkers of ovarian cancer and cysts Reproductive Block 1 Lecture By: Reem Sallam, MD, MSc, PhD.
Plasma proteins Lecture 3.
Eleni Galani Medical Oncologist
Tumor Markers: Clinical Usefulness
Tumor Markers By: dr. hassan el-banna.
Biomarkers Andrew McNaught BME. What is a biomarker? Gives us the ability to analyze organ function, diagnose diseases in a non-invasive way. Biomarkers.
بسم الله الرحمن الرحيم.
Integrated Cancer Screening Education Modules.  A disease that starts in the cells  Genes inside cells order growth, work, reproduction and death What.
Epidemiology of cancer:. Cancer incidence:  In males: Cancers of the lung, prostate, and colon are the leading causes of cancer deaths.  In females.
Another way to think of cancer is “Mitosis Run Amok.”
EKUSILENI CLINICAL LABORATORY
Tumor Markers Lecture two By Dr. Reem Sallam. Objectives  To briefly enumerate the most commonly used methods to test for tumor markers  To describe.
Role of Biomarkers in Management of Prostate Cancer Dr. Angela Amayo Specialist Pathologist 13 th April 2012.
OF COLOREATAL CANCER USING SEROLOGIC TUMOR MARKERS DIAGNOSIS & MANAGEMENT.
 Cancer is a group of more than 100 diseases that develop over time › Involve the uncontrolled division of the body’s cells  Cancer is the 2 nd leading.
Tumor markers Present; by Dr. Andalib Isfahan Medical School
Clinical Division of Oncology Department of Medicine I Medical University of Vienna, Austria Tumormarkers.
وما أوتيتم من العلم إلا قليلاً. Prepared by: Abdo A Elfiky.
Tumor Markers.
Breast Cancer By: Christen Scott.
Principles of Surgical Oncology Done by : 428 surgery team surgery team.
Male Reproductive System Kristine Krafts, M.D.. Male Reproductive System Outline Testis Prostate.
6/2/2016Naglaa Alhusseini1 TUMOR MARKERS Naglaa Fathy Alhusseini Ass.Prof. of Biochemistry and Molecular Biology
Tumor Markers American cancer society British Journal of Cancer By B.Heidari.
Breast Cancer. Breast cancer is a disease in which malignant cells form in the tissues of the breast – “National Breast Cancer Foundation” The American.
Biochemical markers for diagnosis of diseases and follow up Dr. Rana Hasanato Associate professor and consultant Head of clinical chemistry department.
Laboratory Diagnosis of Cancer 1.Histological methods 2.Cytopathology - FNAC/Exfoliative 3.Immunohistochemistry/ EM 4.Molecular diagnosis 5.Tumor Markers.
Cancer Over the last decade, improvements in early detection and treatment of cancer have resulted in improved survival and a decline in mortality for.
Principles of Surgical Oncology
Tumor Markers.
Introduction and overview of CA19-9 CA19-9 is a tumour associated antigen found in the blood serum. CA 19-9 is also known as the Sialylated Lewis-antigen.
Chapter 13: Reducing Your Risk of Cancer Cancer is a group of diseases characterized by uncontrolled, disorderly cell growth Cancer is the second-leading.
Biomarkers of ovarian cancer and cysts Reproductive Block 1 Lecture Dr. Usman Ghani.
Unit 6: Tumor markers. Introduction… Cancer is the second leading cause of death in North America, accounting for > 2.7 million deaths annually Although.
Zoe Ryan Carcinoembryonic Antigen (CEA). What is CEA? Carcinoembryonic antigen is a protein found in the blood of some adults who have certain cancers.
INDICATORS OF HEALTH STATUS Burden of disease Disability Adjusted Life Year (DALY) Health status Morbidity Life expectancy Prevalence Mortality Incidence.
Cell Biology & Cancer Unit Objective 1 Cancer types, incidence, pre-disposition, and risk factors Biomedical Technology.
Biomarkers of ovarian cancer and cysts Reproductive Block 1 Lecture Dr. Usman Ghani.
Lecture # 43 NEOPLASIA - 4 Dr. Iram Sohail Assistant Professor Pathology College Of Medicine Majmaah University.
Common pitfall in Oncology Luangyot Thongthieang, MD MEDICAL ONCOLOGY UNIT INTERNAL MEDICINE, KHONKAEN HOSPITAL.
Tumor markers 1111.
Screening for Ovarian Cancer
Ovarian tumor markers Associate Professor Fariba Behnamfar
Male Reproductive System
The Value of Measurement of Circulating Tumor Cells in Hepatocellular Carcinoma Nashwa Sheble, Gehan Hamdy, Moones A Obada, Gamal Y Abouria, Fatma Khalaf.
EPIDEMIOLOGY.
Cell Biology and Cancer
Male and Female Reproductive Health Concerns
Biomedical Technology
Cancer screening PROF .MAZIN AL-HAWAZ.
Cell Biology and Cancer Unit H.
Tumor Marker Tests.
Presented By: Sally Saad Mandour Esawy
Cancer.
High levels of preventable chronic disease, injury and mental health problems Cancer.
ד"ר שרית בר ששת בי"ח בילינסון
Healthy Choices = Healthy Living
It is estimated that more than 1
Biomedical Technology
Biochemical markers for diagnosis of diseases and follow up
Presentation transcript:

SURGICAL ONCOLOGY AND TUMOR MARKERS

SURGICAL ONCOLOGY AND TUMOR MARKERS Cancer is a diverse group of diseases collectively characterized by an unregulated proliferation of undifferentiated cells that invade local tissue and may spread or metastasize to other parts of the body, so Cancer cells are psychopaths. They have no respect for the rights of other cells.

EPIDEMIOLOGY One in four deaths in the United States is due to cancer, second only to deaths from heart disease. In 2011, approximately 1,596,670 new cancer cases and 571,950 cancer deaths were projected in the United States. In children between the ages of 1 and 14 years, cancer is second only to deaths by accidents

CANCER BIOLOGY malignant transformation is the result of cells acquiring four functional capabilities: (1) the ability for self-suffi cient growth (2) an insensitivity to antigrowth signals, (resist signals that inhibit growth) (3) the ability to evade apoptosis (programmed cell death), and (4) the capacity of limitless replication.

Two other functional capabilities acquired by cancer cells include sustained angiogenesis and tissue invasion, but these changes occur not only within the cancer cell itself but also in its interaction and relationship with other elements.

The following factors may suggest the presence of a hereditary cancer The following factors may suggest the presence of a hereditary cancer. 1. Tumor development at a much younger age than usual 2. Presence of bilateral disease 3. Presence of multiple primary malignancies 4. Presentation of a cancer in the less affected sex (e.g., male breast cancer) 5. Clustering of the same cancer type in relatives 6. Occurrence of cancer in association with other conditions such as mental retardation or pathognomonic skin lesions

TUMOR MARKERS Prognostic and Predictive Tissue Markers Tumor markers are substances that can be detected in higher than normal amounts in the serum, urine, or tissues of patients with certain types of cancer. Tumor markers are produced either by the cancer cells themselves or by the body in a response to the cancer.

the term prognostic marker generally is used to describe molecular markers that predict disease-free survival, disease-specific survival, and overall survival, For example, ideal prognostic tumor markers would be able to help determine which patients with node-negative breast cancer are at higher risk of relapse so that adjuvant systemic therapy could be given only to that group.

Predictive markers are markers that can prospectively identify patients who will benefit from a certain therapy. For example in breast cancer, estrogen receptor (ER) and HER2 assessment can identify patients who can benefit from antiestrogen therapies (e.g., tamoxifen) and anti-HER2 targeted therapies (e.g., trastuzumab), respectively

Serum Markers Serum markers are under active investigation because they may allow early diagnosis of a new cancer or may be used to follow cancer response to therapy or monitor for recurrence.

when a tumor marker is used to monitor recurrence, it is important to be certain that the level of the tumor marker was elevated before primary therapy. Moreover, tumor marker levels can be elevated in benign conditions.

Many tumor markers are not specific for a certain type of cancer and can be elevated with more than one type of tumor.

Prostate-Specific Antigen Prostate-Specific Antigen. Prostate-specific antigen (PSA) is an androgen-regulated serine protease produced by the prostate epithelium. PSA is normally present in low concentrations in the blood of all adult males. PSA levels may be elevated in the blood of men with benign prostate conditions such as prostatitis and benign prostatic hyperplasia, as well as in men with prostate cancer.

PSA levels have been shown to be useful in evaluating the effectiveness of prostate cancer treatment and monitoring for recurrence after therapy. In monitoring for recurrence, a trend of increasing levels is considered more significant than a single absolute elevated value.

Carcinoembryonic Antigen Carcinoembryonic Antigen. Carcinoembryonic antigen (CEA) is a glycoprotein found in the embryonic endodermal epithelium. Elevated CEA levels have been detected in patients with primary colorectal cancer as well as in patients with breast, lung, ovarian, prostate, liver, and pancreatic cancer

Levels of CEA also may be elevated in benign conditions, including diverticulitis, peptic ulcer disease, bronchitis, liver abscess, and alcoholic cirrhosis, especially in smokers and in elderly persons.

CEA measurement is most commonly used in the management of colorectal cancer. However, the appropriate use of CEA testing in patients with colorectal cancer has been debated. Use of CEA level as a screening test for colorectal cancer is not recommended

CEA levels may be useful if obtained preoperatively and postoperatively in patients with a diagnosis of colorectal cancer. Preoperative elevation of CEA level is an indicator of poor prognosis.

Alpha-Fetoprotein. Alpha-fetoprotein (AFP) is a glycoprotein normally produced by a developing fetus. AFP levels decrease soon after birth in healthy adults. An elevated level of AFP suggests the presence of either primary liver cancer or a germ cell tumor of the ovary or testicle.

Benign conditions that can cause elevations of AFP include cirrhosis, hepatic necrosis, acute hepatitis, chronic active hepatitis, , and pregnancy

The sensitivity of an elevated AFP level for detecting HCC is approximately 60%. AFP is considered to be sensitive and specific enough to be used for screening for HCC in high risk population. With improvement technology a larger proportion of patient diagnosed with HCC are now AFP Seronegative.

Thank you